

Vancomycin – intermittent regimen

Newborn use only

2024

Alert	New South Wales Antimicrobial Stewardship category: Restricted after 72 hours. Continuous infusion regimen optimises achievement of steady state target concentration with fewer dose adjustments and a lower total daily dose in comparison to intermittent regimen.																																
Indication	Treatment of potentially life-threatening infections (untreatable with less toxic antimicrobials) including methicillin resistant staphylococcus aureus (MRSA), coagulase negative staphylococcal epidermidis (CONS), Strep. viridans, Strep. bovis, enterococci.																																
Action	Bactericidal agent which interferes with cell wall synthesis, inhibits RNA synthesis and alters plasma membrane function.																																
Drug type	Glycopeptide antibiotic.																																
Trade name	DBL Vancomycin powder for infusion, Vancocin CP powder for infusion, Vancomycin Alphapharm powder for infusion, vancomycin Juno powder for infusion, vancomycin viatris powder for infusion.																																
Presentation	Vancomycin hydrochloride 500 mg vial Vancomycin hydrochloride 1000 mg vial																																
Dose	<p>ANMF consensus: Dosing schedule as per table below¹</p> <table border="1"> <thead> <tr> <th>Corrected Gestational Age/Postmenstrual Age</th> <th>Postnatal Age</th> <th>Dose</th> <th>Dose interval</th> </tr> </thead> <tbody> <tr> <td><30⁺⁰ weeks</td> <td>0–2 days</td> <td>15 mg/kg</td> <td>18 hourly</td> </tr> <tr> <td>< 30⁺⁰ weeks</td> <td>3+ days</td> <td>15 mg/kg</td> <td>12 hourly</td> </tr> <tr> <td>30⁺⁰–36⁺⁶ weeks</td> <td>0–14 days</td> <td>15 mg/kg</td> <td>12 hourly</td> </tr> <tr> <td>30⁺⁰–36⁺⁶ weeks</td> <td>15+ days</td> <td>15 mg/kg</td> <td>8 hourly</td> </tr> <tr> <td>37⁺⁰–44⁺⁶ weeks</td> <td>0–7 days</td> <td>15 mg/kg</td> <td>12 hourly</td> </tr> <tr> <td>37⁺⁰–44⁺⁶ weeks</td> <td>8+ days</td> <td>15 mg/kg</td> <td>8 hourly</td> </tr> <tr> <td>≥ 45⁺⁰ weeks</td> <td>0+ days</td> <td>15 mg/kg</td> <td>6 hourly</td> </tr> </tbody> </table> <p>Monitor drug concentrations as per monitoring section. Severe sepsis: Consider giving a loading dose of 20 mg/kg/dose in suspected severe sepsis including MRSA, bone infection, meningitis, endocarditis. However, data in neonates are limited.</p>	Corrected Gestational Age/Postmenstrual Age	Postnatal Age	Dose	Dose interval	<30 ⁺⁰ weeks	0–2 days	15 mg/kg	18 hourly	< 30 ⁺⁰ weeks	3+ days	15 mg/kg	12 hourly	30 ⁺⁰ –36 ⁺⁶ weeks	0–14 days	15 mg/kg	12 hourly	30 ⁺⁰ –36 ⁺⁶ weeks	15+ days	15 mg/kg	8 hourly	37 ⁺⁰ –44 ⁺⁶ weeks	0–7 days	15 mg/kg	12 hourly	37 ⁺⁰ –44 ⁺⁶ weeks	8+ days	15 mg/kg	8 hourly	≥ 45 ⁺⁰ weeks	0+ days	15 mg/kg	6 hourly
Corrected Gestational Age/Postmenstrual Age	Postnatal Age	Dose	Dose interval																														
<30 ⁺⁰ weeks	0–2 days	15 mg/kg	18 hourly																														
< 30 ⁺⁰ weeks	3+ days	15 mg/kg	12 hourly																														
30 ⁺⁰ –36 ⁺⁶ weeks	0–14 days	15 mg/kg	12 hourly																														
30 ⁺⁰ –36 ⁺⁶ weeks	15+ days	15 mg/kg	8 hourly																														
37 ⁺⁰ –44 ⁺⁶ weeks	0–7 days	15 mg/kg	12 hourly																														
37 ⁺⁰ –44 ⁺⁶ weeks	8+ days	15 mg/kg	8 hourly																														
≥ 45 ⁺⁰ weeks	0+ days	15 mg/kg	6 hourly																														
Dose adjustment	<p>Therapeutic hypothermia: Measure trough concentration prior to 2nd dose² and wait for the result before administering the dose.</p> <p>Renal impairment:</p> <ul style="list-style-type: none"> For infants with renal impairment, consider using an antibiotic without nephrotoxicity. If vancomycin is used, measure trough concentration before 2nd dose and wait for the result before administering the dose. Adjust the dosage interval^{5, 21} to achieve a trough concentration 10–20 mg/L. Repeat trough level before the next dose after each dosage adjustment or before every 3rd dose for infants within the target range. <p>Hepatic impairment: Not applicable.</p> <p>ECMO: Current evidence is insufficient to recommend a specific dose adjustment.</p>																																
Maximum dose	Not applicable																																
Total cumulative dose	Not applicable																																
Route	IV																																
Preparation	<p>500mg VIAL Add 10 mL of water for injection to the 500 mg vial to make a 50 mg/mL solution.</p> <p>FURTHER DILUTE Draw up 2 mL (100 mg of vancomycin) of the above solution and add 18 mL glucose 5% or sodium chloride 0.9% to make a final volume of 20 mL with a final concentration of 5 mg/mL.</p> <p>1g VIAL Add 20 mL of water for injection to the 1g vial to make a 50 mg/mL solution.</p> <p>FURTHER DILUTE</p>																																

	<p>Draw up 2 mL (100 mg of vancomycin) of the above solution and add 18 mL glucose 5% or sodium chloride 0.9% to make a final volume of 20 mL with a final concentration of 5 mg/mL.</p> <p><u>Special circumstances (10 mg/mL concentration- can only be given via central line)</u> For fluid restricted infants, vancomycin can be diluted to 10 mg/mL concentration. <u>Preparing 10 mg/mL concentration using 500mg VIAL</u> <i>Add 10 mL of water for injection to the 500 mg vial to make a 50 mg/mL solution</i> <u>Further Dilute</u> <i>Draw up 4 mL (200 mg of vancomycin) of the above solution and add 16 mL glucose 5% or sodium chloride 0.9% to make a final volume of 20 mL with a final concentration of 10 mg/mL.</i> <i>To prepare 10 mg/mL concentration</i> <u>Preparing 10 mg/mL concentration using 1g VIAL</u> <i>Add 20 mL of water for injection to the 1g vial to make a 50 mg/mL solution</i> <u>Further Dilute</u> <i>Draw up 4 mL (200 mg of vancomycin) of the above solution and add 16 mL glucose 5% or sodium chloride 0.9% to make a final volume of 20 mL with a final concentration of 10 mg/mL.</i></p>																								
Administration	<p>IV infusion over ONE hour. Adequately flush the intravenous lines before and after administration of vancomycin.</p>																								
Monitoring	<p>Monitor renal function, full blood count, hearing function and serum vancomycin concentrations. Measure trough vancomycin concentration immediately prior to 3rd dose with the exception of:</p> <ol style="list-style-type: none"> 1. <29⁺⁰ CGA weeks – before 2nd dose, 2. therapeutic hypothermia – before 2nd dose and 3. renal impairment – before 2nd dose. Refer to renal impairment section below. <p>Target trough concentration 10–20 mg/L.</p> <p>After any change in dose or frequency - Check trough concentration prior to 4th dose, except 3 conditions listed above where trough concentrations are required prior to 2nd dose. Once target trough levels are reached, measure trough levels every 3 days prior to consecutive doses. More frequent monitoring may be required in renal impairment, infants receiving other nephrotoxic drugs or suspected severe sepsis.</p> <p>If a peak concentration is required to guide dosing, perform this 1 hour after completion of infusion, and target a peak concentration 20-40 mg/L.^{3,4,5} (1, 2)</p> <p>Recommended adjustment based on trough concentration:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center;">Trough concentration</th> <th style="text-align: center;">Daily dose</th> <th style="text-align: center;">Frequency Preferred</th> <th style="text-align: center;">Example</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;"><5 mg/L</td> <td style="text-align: center;">Increase by 50-75%</td> <td style="text-align: center;">Increase</td> <td style="text-align: center;">Current daily dose X 1.5-1.75 = NEW DAILY DOSE</td> </tr> <tr> <td style="text-align: center;">5-9.9 mg/L</td> <td style="text-align: center;">Increase by 25-50%</td> <td style="text-align: center;">Increase</td> <td style="text-align: center;">Current daily dose X 1.25-1.5 = NEW DAILY DOSE</td> </tr> <tr> <td style="text-align: center;">10-20 mg/L</td> <td style="text-align: center;">No Change</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td style="text-align: center;">20.1-25 mg/L</td> <td style="text-align: center;">Decrease by 25-50% and do trough levels prior to next dose.</td> <td style="text-align: center;">Decrease</td> <td style="text-align: center;">Current daily dose X 0.5-0.75 = NEW DAILY DOSE</td> </tr> <tr> <td style="text-align: center;">>25 mg/L</td> <td style="text-align: center;">WITHHOLD DOSE. Repeat trough levels 12 hourly until concentration 10-20mg/L</td> <td style="text-align: center;">Decrease</td> <td style="text-align: center;">Current daily dose X 0.5 = NEW DAILY DOSE</td> </tr> </tbody> </table> <p>Changing frequency of administration is preferred against changing dose.</p>	Trough concentration	Daily dose	Frequency Preferred	Example	<5 mg/L	Increase by 50-75%	Increase	Current daily dose X 1.5-1.75 = NEW DAILY DOSE	5-9.9 mg/L	Increase by 25-50%	Increase	Current daily dose X 1.25-1.5 = NEW DAILY DOSE	10-20 mg/L	No Change	-	-	20.1-25 mg/L	Decrease by 25-50% and do trough levels prior to next dose.	Decrease	Current daily dose X 0.5-0.75 = NEW DAILY DOSE	>25 mg/L	WITHHOLD DOSE. Repeat trough levels 12 hourly until concentration 10-20mg/L	Decrease	Current daily dose X 0.5 = NEW DAILY DOSE
Trough concentration	Daily dose	Frequency Preferred	Example																						
<5 mg/L	Increase by 50-75%	Increase	Current daily dose X 1.5-1.75 = NEW DAILY DOSE																						
5-9.9 mg/L	Increase by 25-50%	Increase	Current daily dose X 1.25-1.5 = NEW DAILY DOSE																						
10-20 mg/L	No Change	-	-																						
20.1-25 mg/L	Decrease by 25-50% and do trough levels prior to next dose.	Decrease	Current daily dose X 0.5-0.75 = NEW DAILY DOSE																						
>25 mg/L	WITHHOLD DOSE. Repeat trough levels 12 hourly until concentration 10-20mg/L	Decrease	Current daily dose X 0.5 = NEW DAILY DOSE																						

	<p>< 5 mg/L – increase total daily dose by 50–75% (i.e. 1.5-1.75 times)) by either increasing frequency (preferred) or increasing each dose.</p> <p>5–9.9 mg/L – increase total daily dose by 25–50% (i.e. 1.25-1.5 times) by either increasing frequency (preferred) or increasing each dose.</p> <p>10–20 mg/L – no change in dose required.</p> <p>20.1-25 mg/L – decrease total daily dose by 25-50% by decreasing the frequency (preferred) or decreasing each dose.</p> <p>>25 mg/L – withhold dose. Repeat trough concentration 12 hourly until plasma concentration is 10–20 mg/L, then restart at a dose decreased by 50% (i.e. 0.5 times) by decreasing frequency (preferred) or decreasing each dose.</p> <p>Example for adjusting dose by increasing / decreasing frequency: Calculate current total daily dose (e.g. 15 mg 8 hourly = 45 mg/day). If trough <5 mg/L – Increase total daily dose by 1.5 times (i.e. 45 x 1.5 = 67.5 mg/day) and decide on achieving this total daily dose by either increasing the frequency or increasing the dose.</p> <p>If trough 26 mg/L - withhold next dose, repeat trough level 12 hourly, once repeat concentration is <20mg/L, decrease total daily dose to 0.5 times (i.e. 45 x 0.5 = 22.5 mg/day) and decide on achieving this total daily dose by either decreasing the frequency or decreasing the dose.</p> <p>Renal impairment For infants with renal impairment, consider using antibiotic without nephrotoxicity. If vancomycin is used, perform a trough concentration before the 2nd dose, irrespective of corrected gestational age.</p>
Contraindications	Known hypersensitivity to vancomycin.
Precautions	Use with caution in renal impairment or those receiving other nephrotoxic, neurotoxic or ototoxic drugs.
Drug interactions	<p>Potential ototoxic or nephrotoxic drugs – e.g. amphotericin B, aminoglycosides, piperacillin-tazobactam, concurrent use requires careful monitoring.</p> <p>Diuretics – potent diuretics (e.g., furosemide) may add to the ototoxic effect.</p> <p>Neuromuscular blocking agents (e.g. pancuronium, suxamethonium, vecuronium) – vancomycin may enhance neuromuscular blockade.</p> <p>There have been reports that the frequency of infusion-related events (including hypotension, flushing, erythema, urticaria, and pruritus) increases with the concomitant administration of anaesthetic agents. Infusion-related events may be minimised by the administration of Vancomycin as a 60-minute infusion prior to anaesthetic induction.</p>
Adverse reactions	<p>Infusion-related events: Rapid infusion may cause red man syndrome – a predominately histamine-mediated reaction with pruritus, tachycardia, hypotension and rash. It appears rapidly and usually dissipates in 30–60 minutes, but may persist for several hours. Increasing the infusion time usually eliminates the risk for subsequent doses.</p> <p>Reversible neutropenia - usually starting one week or more after onset of therapy with vancomycin.</p> <p>Thrombocytopenia.</p> <p>Pancytopenia – rare.</p> <p>Anaphylactic reactions may occur. Severe reactions may require treatment with adrenaline (epinephrine), corticosteroids or oxygen.</p> <p>Phlebitis and tissue irritation and necrosis may occur, especially after extravasation. Intramuscular injection is not recommended.</p> <p>Ototoxicity and nephrotoxicity – these are more pronounced with the addition of other medications such as aminoglycosides or furosemide.</p> <p>Neutropenia and thrombocytopenia have been reported in adults. Risk is increased with prolonged therapy >1 week but they appear to be reversible when vancomycin is discontinued.</p>
Overdose	Supportive care. For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).
Compatibility	Fluids: Glucose 5%, glucose 10%, sodium chloride 0.9%, dextrose 5% in sodium chloride 0.9%

	<p>Y site: amino acid solutions and fat emulsions, acetaminophen, acetylcysteine, aciclovir, adrenaline (epinephrine) hydrochloride, alfentanil HCL, alprostadil, alteplase, amikacin sulfate, amiodarone, amoxicillin sodium/clavulanate potassium, ampicillin, anidulafungin, atenolol, atracurium, atropine sulfate, azithromycin, buprenorphine, calcium chloride, calcium gluconate, caspofungin, chlorpromazine, cefpirome sulfate, ciprofloxacin, cisatracurium, clarithromycin, clindamycin, codeine phosphate, colistimethate Sodium, cyanocobalamin, cycloPHOSphamide , cyclosporine, dexamethasone sodium phosphate, dexmedetomidine HCL, digoxin, diltiazem HCL, dobutamine HCL, dopamine HCL, doxycycline hyclate, enalaprilat, epinephrine HCL, ertapenem Sodium, erythromycin lactobionate, esmolol, famotidine, fentanyl, filgrastim, fluconazole, fosfomycin, fosphenytoin, gentamicin sulfate, glycopyrrolate, hydromorphone, insulin regular, isoproterenol HCL, ketamine HCL, labetalol, levetiracetam, lidocaine HCL, linezolid, lorazepam, magnesium sulfate, meropenem/veborbactam, metoprolol, metronidazole, midazolam, milrinone, morphine HCL and sulfate, naloxone, nicardipine, noradrenaline (norepinephrine), octreotide, ondansetron, pamidronate disodium, pancuronium bromide, papaverine, pentobarbital sodium, pentoxifylline, phenobarbital sodium, phentolamine mesylate, phenylephrine HCL, Plasma-Lyte, posaconazole, potassium acetate, potassium chloride, procainamide, propranolol HCL, protamine, pyridoxine, ranitidine HCL, remifentanil, sodium acetate, sodium bicarbonate, sodium nitroprusside, succinylcholine, tacrolimus, thiamine, thiotepe, tigecycline, tobramycin, tolazoline, vasopressin, vecuronium, verapamil, voriconazole, zidovudine, zoledronic acid.</p>
Incompatibility	<p>Fluids: No information.</p> <p>Y-site: Albumin, aminophylline, amphotericin B, amphotericin B cholesteryl sulfate complex, amphotericin B lipid complex, amphotericin B liposome, ampicillin sodium/sulbactam sodium, azathioprine, cloxacillin sodium, dantrolene, daptomycin diazepam, diazoxide, epoetin alfa, fluorouracil, foscarnet, furosemide, ganciclovir, ibuprofen lysine, indometacin, ketorolac, lacosamide, lansoprazole, leucovorin calcium, methylprednisolone sodium succinate, moxifloxacin, omeprazole, oxacillin, phenytoin sodium, sulfamethoxazole/trimethoprim, theophylline urokinase, valproate, warfarin.</p> <p>Caution/variable: Aztreonam, ampicillin sodium, cefamandole, cefazolin, cefepime, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, heparin sodium, hydralazine, hydrocortisone sodium succinate, imipenem/cilastain, meropenem, pantoprazole, piperacillin sodium, piperacillin sodium/tazobactam sodium, propofol, rocuronium, , ticarcillin disodium, ticarcillin/clavulanate,</p>
Stability	Administer immediately, discard unused portion of reconstituted solution.
Storage	Store below 25°C. Protect from light.
Excipients	DBL Vancomycin Hydrochloride, Vancocin CP: Disodium acetate.
Special comments	Extravasation may cause tissue necrosis.
Evidence	<p>Background</p> <p>Vancomycin is a water-soluble glycopeptide, has a limited plasma protein binding capacity and is mainly eliminated renally by glomerular filtration, although its elimination is further modulated by renal tubular transport.³ Vancomycin is active against gram-positive bacteria. Staphylococcus epidermis, including methicillin- resistant strains, are inhibited by vancomycin concentrations of 1–4 mg/mL; Staphylococcus pyogenes, Streptococcus pneumoniae, and Streptococcus viridans are susceptible to 2 mg/mL; Bacillus spp. are inhibited by 2 mg/mL, and Clostridium spp. by 0.39–6 mg/mL.³</p> <p>Pharmacokinetic studies demonstrate variability, which is only in part explained by weight, age, or creatinine level.[1-4] This variability necessitates the use of therapeutic drug monitoring (TDM) of trough concentrations to ensure effectiveness and avoid nephrotoxicity. In contrast, the quantification of peak concentrations may provide no additional monitoring value.¹</p> <p>Because vancomycin activity against S. aureus is primarily exposure-dependent, the 24-hour area under the concentration-time curve (AUC₀₋₂₄) divided by the MIC (AUC₀₋₂₄/MIC) is a better predictor of efficacy. Vancomycin, a glycopeptide, is administered to treat (suspected) serious gram-positive infections caused by Staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative Staphylococci (CoNS).^{4,5} It is almost exclusively eliminated unchanged by glomerular filtration and to some extent by tubular secretion. The 2020 recommendation by The Infectious Diseases Society of America (IDSA), Paediatric Infectious Diseases Society, and the society of Infectious Diseases Pharmacists</p>

recommend a target AUC/MIC of 400-600 in adult population with serious MRSA infections. In their previous 2011 guideline, they recommended higher trough concentration of 15-20 mg/L, but it was associated with nephrotoxicity and 2020 guidelines do not recommend higher trough concentrations of 15-20 mg/L anymore.^{1,2} There are limited clinical outcomes data to support any AUC targets for neonatal population. Pharmacokinetics and pharmacodynamics of vancomycin is different in neonates. It is unbound fraction of vancomycin that is pharmacologically active, which could be higher in neonates due to lower amount of serum albumin.⁵ Vancomycin disposition in neonates also depends on weight, age, and renal function.^{4,5}

Efficacy

Clinical trials of vancomycin in newborn infants are largely underpowered so the relative efficacy of various antibiotic strategies is unclear.

Treatment of neonatal sepsis: Two RCTs have compared the efficacy of vancomycin to other antibiotics (linezolid or cefazolin). There was no significant difference in clinical cure rates in either of these trials.^{9,10} Gwee et al 2018 compared intermittent intravenous (IV) dosing using the British Neonatal Formulary (BNF) dosage guidance versus continuous IV [loading dose of 15mg/kg over 1 hour then continuous infusion]. There was no difference in time to clearance of organism or mortality.¹¹ For further details, please refer to vancomycin continuous infusion formulary.

NeoVanc consortium is a multicentre European group studying the optimal dosing for vancomycin in neonates. This consortium includes many NICUs from European countries. The standard dosing regimen practised by NeoVanc consortium is in the table below.^{12,13}

Corrected Gestational Age/Postmenstrual Age	Interval
<29 ⁺⁰ weeks	24 hourly
29 ⁺⁰ -35 ⁺⁶ weeks	12 hourly
≥36 ⁺⁰ weeks	8 hourly

NeoVanc group conducted an open-label, multicentre, Phase IIb, randomised, parallel group, non-inferiority trial recruiting participants across 22 NICUs in 5 European countries.^{12,13} Infants were randomised in a 1:1 allocation ratio for each regimen. Standard group received 10±2 day course of vancomycin using the dosing regimen given in the table above. Intervention group received a 5±1 day course of loading dose of 25 mg/kg followed 8-12 hours later by a maintenance dose of 15 mg/kg 12 hourly (PMA≤35 weeks) or 8 hourly (PMA>35 weeks). There was no clear benefit with shorter course with loading regimen over the standard regimen. There was also a concern that hearing in the loading dose with shorter duration group had 30% abnormal hearing screening, compared to 15% in standard regimen (adjusted risk ratio 1.72; 95% CI 1.0-2.9). Long term follow-up, secondary PK and microbiological outcomes are not yet available from this study. The findings of this trial do not justify shorter and higher dose regimen in neonates.

ANMF group is reviewing the Neovanc consortium recommendations and awaiting Neovanc group's feedback on target trough concentrations and dose adjustments.

Prevention of infection: A systematic review conducted in both full term and preterm infants found 3 small studies (total number=290 neonates).¹⁴ Two of the studies used vancomycin prophylaxis and 1 study used amoxicillin.¹⁵⁻¹⁷ Cooke 1997 RCT included only VLBW infants.¹⁷ The experimental group in this trial used 5 mg/kg twice a day through the duration of parenteral nutrition/central line. Spafford et al 1994 added vancomycin 25 µg/mL to PN solution to all neonates on PN.¹⁵ Harms et al 1995 used IV amoxicillin 100 mg/kg/day 3 times a day in all neonates with central lines.¹⁶ Meta analysis found that prophylactic antibiotics in neonates with central venous lines decreased the rates of proven bacterial sepsis (typical RR 0.38, 95% CI 0.18-0.82). No resistant organisms were identified in any of the studies. However prophylactic antibiotics had no impact on their primary outcome of mortality. The authors of the review concluded that prophylactic systemic antibiotics in neonates with a central venous catheter reduces the rate of proven or suspected septicaemia. However, there was no significant difference in mortality, a lack of data on long-term neurodevelopmental outcome and of data pertaining to the potentially significant disadvantages of this approach such as the selection of resistant organisms. The routine use of prophylactic antibiotics in infants with central venous catheters in neonatal units cannot currently be recommended.¹⁴ Three other RCTs, not included in the systematic review reported similar effects of prophylactic vancomycin in infants

	<p>with or without central lines. A prospective, randomized study by Kacia et al, 1994¹⁹ evaluated the effectiveness of a continuous low-dose vancomycin infusion to prevent nosocomial gram-positive bacteraemia initiated within the first 2 weeks of life in neonates weighing <1500 gm. Seventy-one infants received constant infusion of vancomycin (25/~g/ml) mixed with their total parenteral nutrition solution; 70 infants served as control subjects. Administration of vancomycin was begun at a mean age of 5.4 ± 2.9 days. Infants had mean serum vancomycin concentrations of 2.4 µg/ml, and received vancomycin for a mean of 11± 7 days. No vancomycin-resistant organisms were detected in surveillance cultures during the 2-year study period. Control group had significantly higher gram positive sepsis, compared to vancomycin group (34% vs 1.4%, respectively.¹⁹ Baier et al, 1998, conducted similar RCT in very low birthweight infants using similar vancomycin dose (25 µg/mL) in PN solution.²⁰ There was a significant reduction in the number of coagulase-negative staphylococcal (CONS) bacteraemia (defined as isolation of the same organism from two positive blood cultures) during PN (5 vs. 0; P= 0.037) as well as the total number of bacteraemia and fungaemia (9 vs. 1; P= 0.036). The total number of hospital days (108±13 vs. 76±6; P= 0.039) were reduced in infants receiving vancomycin. Infants with birth weights of< 1000 g who received corticosteroids for treatment of chronic lung disease benefitted most from treatment. No vancomycin-resistant strains of CONS or enterococci were detected during the study period.</p> <p>Intraventricular antibiotics for bacterial meningitis or shunt infections in neonates: In a single trial that enrolled infants with gram-negative meningitis and ventriculitis, the use of intraventricular gentamicin in addition to intravenous antibiotics resulted in a three-fold increased RR for mortality compared to standard treatment with intravenous antibiotics alone. No trial used intraventricular vancomycin. Based on this result, intraventricular antibiotics as tested in this trial should be avoided.²¹ Arnell et al 2007 reported 10 children (0 to 15 years) with intraventricular shunt infections initially treated with IV antibiotics for at least 3 days, but this treatment did not sterilise the CSF.²² After externalisation of the ventricular catheter, high-dose intraventricular treatment with daily instillations of vancomycin or gentamicin with trough concentrations held at high levels of 7 to 17 mg/L for both antibiotic agents resulted in quick sterilisation of the CSF, a low relapse rate, and survival of all patients. The intraventricular vancomycin dose varied between 1 and 10 mg per day. ANMF consensus is not to recommend any intraventricular antibiotic until further trials indicate the safety of these antibiotics via this route.</p> <p>Treatment of necrotising enterocolitis: No trial included use of vancomycin.²³</p> <p>Prevention of necrotising enterocolitis: Prophylactic oral vancomycin reduced the incidence of NEC in low birth weight infants. However concerns about adverse outcomes persist, particularly related to the development of resistant bacteria.^{24,25} [LOE II GOR D]</p> <p>Therapeutic hypothermia (TH): There are no published data regarding the use of vancomycin during treatment with TH in neonates. A population pharmacokinetic study from children who were being treated with TH post cardiac arrest compared with normothermic controls indicated that in patients with normal renal function vancomycin clearance was reduced by 25%.²</p> <p>ANMF group Recommendation: In infants being treated with TH measure a trough concentration immediately prior to the second dose.</p> <p>Safety:</p> <p>Risk factors for developing nephrotoxicity include high trough concentrations, concomitant treatment with aminoglycosides, piperacillin/tazobactam and/or prolonged therapy (>21 days).⁶</p> <p>Other risk factors include high peak concentrations, high total dose, pre-existing renal failure, and concurrent treatment with amphotericin and/or furosemide. However, the role of these factors in the neonatal population is not well-established. Proper vancomycin TDM minimised both glomerular and tubular nephrotoxicity in two studies in children and neonates. In most cases, nephrotoxicity is reversible, even after high doses. In contrast, there is no proven association between TDM and ototoxicity prevention.⁶</p>
<p>Practice points</p>	
<p>References</p>	<ol style="list-style-type: none"> 1. Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, Sherwin CMT. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. <i>Clinical Pharmacokinetics</i>. 2014;53:581-610. 2. Zane NR, Reedy MD, Gastonguay MR, Himebauch AS, Ramsey EZ, Topjian AA, et al. A Population pharmacokinetic analysis to study the effect of therapeutic hypothermia on vancomycin disposition in children resuscitated from cardiac arrest. <i>Pediatric Critical Care Medicine</i>. 2017;18(7):e290-e7.

3. Brown DL, Lalla CD, Masselink AJ. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug. *Ther Drug Monit.* 2013; 35:443-9.
4. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy.* 2020;77(11):835-64.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clinical infectious diseases.* 2011;52(3):e18-e55.
6. Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review. *Clinics.* 2012;67(7):831-7.
7. Pham JT. Challenges of vancomycin dosing and therapeutic monitoring in neonates. *The Journal of Pediatric Pharmacology and Therapeutics.* 2020;25(6):476-84.
8. Smits A, Pauwels S, Oyaert M, Peersman N, Spriet I, Saegeman V, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. *Eur J Clin Microbiol Infect Dis.* 2018;37:1503-10.
9. Deville JG, Adler S, Azimi PH, Jantusch BA, Morfin MR, Beltran S, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. *The Pediatric infectious disease journal.* 2003;22(9):S158-S63.
10. Cernadas JMC, Jonusas SF, Márquez M, Garsd A, Mariani G, Armadans M. Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin. A non-inferiority, randomized, controlled trial. *Arch Argent Pediatr.* 2014;112(4):308-14.
11. Gwee A, Cranswick N, McMullan B, Perkins E, Bolisetty S, Gardiner K, et al. Continuous versus intermittent vancomycin infusions in infants: a randomized controlled trial. *Pediatrics.* 2019;143(2).
12. Hill LF, Turner MA, Lutsar I, Heath PT, Hardy P, Linsell L, et al. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. *Trials.* 2020;21:1-11.
13. Hill LF, Clements MN, Turner MA, Donà D, Lutsar I, Jacqz-Aigrain E, et al. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. *The Lancet Child & Adolescent Health.* 2022;6(1):49-59.
14. Jardine LA, Inglis GD, Davijes MW. Prophylactic systemic antibiotics to reduce morbidity and mortality in neonates with central venous catheters. *Cochrane database of systematic reviews.* 2008(1).
15. Spafford PS, Sinkin RA, Cox C, Reubens L, Powell KR. Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. *The Journal of pediatrics.* 1994;125(2):259-63.
16. Harms K, Herting E, Kron M, Schiffmann H, Schulz-Ehlbeck H. Randomized, controlled trial of amoxicillin prophylaxis for prevention of catheter-related infections in newborn infants with central venous silicone elastomer catheters. *The Journal of pediatrics.* 1995;127(4):615-9.
17. Cooke R, Nycyk J, Okuonghuae H, Shah V, Damjanovic V, Hart C. Low-dose vancomycin prophylaxis reduces coagulase-negative staphylococcal bacteraemia in very low birthweight infants. *Journal of Hospital Infection.* 1997;37(4):297-303.
18. Möller JC, Nelskamp I, Jensen R, Reiss I, Kohl M, Gatermann S, et al. Comparison of vancomycin and teicoplanin for prophylaxis of sepsis with coagulase negative staphylococci (CONS) in very low birth weight (VLBW) infants. 1997.
19. Kacica MA, Horgan MJ, Ochoa L, Sandler R, Lepow ML, Venezia RA. Prevention of gram-positive sepsis in neonates weighing less than 1500 grams. *The Journal of pediatrics.* 1994;125(2):253-8.
20. Baier RJ, Bocchini Jr JA, Brown EG. Selective use of vancomycin to prevent coagulase-negative staphylococcal nosocomial bacteremia in high risk very low birth weight infants. *The Pediatric infectious disease journal.* 1998;17(3):179-83.
21. Shah SS, Ohlsson A, Shah VS. Intraventricular antibiotics for bacterial meningitis in neonates. *Cochrane Database Syst Rev.* 2012.

	<p>22. Arnell K, Enblad P, Wester T, Sjolín J. Treatment of cerebrospinal fluid shunt infections in children using systemic and intraventricular antibiotic therapy in combination with externalization of the ventricular catheter: efficacy in 34 consecutively treated infections. <i>J Neurosurg.</i> 2007;107:213-9.</p> <p>23. Shah D, Sinn JKH. Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. <i>Cochrane Database Syst Rev.</i> 2012.</p> <p>24. Bury RG, Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. <i>Cochrane Database Syst Rev.</i> 2001.</p> <p>25. Siu YK, Ng PC, Fung SC, Lee CH, Wong MY, Fok TF, So KW, Cheung KL, Wong W, Cheng AF. Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1998;79:F105-9.</p> <p>26. Merative™ Micromedex® Complete IV Compatibility (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: April/19/2024)</p>
--	---

VERSION/NUMBER:	DATE
Original: 1.0	8/08/2015
Revised	
1.1	7/07/2016
1.2	12/12/2016
1.3	6/07/2017
1.4	10/08/2017
2.0	15/04/2017
2.1	23/04/2019
2.2	25/02/2020
2.3	16/11/2020
Current: 3.0	24/03/2023
Current 3.0 (Minor errata)	20/04/2024
REVIEW	24/03/2028

Authors of the current version

Author/s	Srinivas Bolisetty
Evidence Review	Srinivas Bolisetty
Expert review	Tony Lai, Brendan McMullan, Phoebe Williams
Nursing Review	Eszter Jozsa, Bryony Malloy
Pharmacy Review	Mohammad Irfan Azeem, Susannah Brew
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, Rebecca Barzegar, Rebecca O’Grady, Mohammad Irfan Azeem, Helen Huynh, Martin Kluckow, Michelle Jenkins, Stephanie Halena, Susannah Brew, Simarjit Kaur, Kerryn Houghton, Natalia Sronic, Renae Gengaroli
Final editing	Srinivas Bolisetty
Electronic version	Cindy Chen, Thao Tran, Helen Huynh, Ian Callander
Facilitator	Srinivas Bolisetty

Citation for the current version

Bolisetty S, Lai T, McMullan B, Williams P, Azeem MI, Brew S, Jozsa E, Malloy B, Phad N, Mehta B, Barzegar R, Kluckow M, Tran T, O’Grady R, Huynh H, Jenkins M, Halena S, Kaur S, Houghton K, Sronic N, Gengaroli R, Chen C, Callander I. Vancomycin Intermittent. Consensus formulary by the Australasian Neonatal Medicines Formulary group. Version 3 (minor errata), dated 20 April 2024. www.anmfonline.org